Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24375312 | 0.76 | KMT2A (0.33) | LMNANPC1MITFTP53RAB9A | |
| SCHEMBL24120274 | 0.76 | IDH1 (0.41) | LMNAALDH1A1POLBMAPTL3MBTL1 | |
| SCHEMBL10197346 | 0.72 | INMT (0.30) | — | |
| SCHEMBL791300 | 0.69 | — | — | |
| SCHEMBL11922777 | 0.67 | — | — | |
| SCHEMBL11316991 | 0.67 | — | — | |
| SCHEMBL1850573 | 0.67 | — | — | |
| SCHEMBL589073 | 0.67 | — | — | |
| SCHEMBL21093432 | 0.67 | — | — | |
| SCHEMBL15930117 | 0.67 | ALDH1A1 (0.38) | LMNANPC1MITFTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20210198246-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2021-07-01 | — | — | US | disclosed |
| US-9856259-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160075712-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2016-03-17 | — | — | US | disclosed |
| US-20100273805-A1 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198246-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | APLNR, AP2B1, AP3B1 | CA12 1856/4885BRD4 2963/4885BRPF1 2309/4885 |
| US-20160075712-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | CA12 674/4885BRD4 1213/4885BRPF1 3939/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | CA12 2648/4885BRD4 2416/4885BRPF1 4286/4885 |
| US-20100273805-A1 | SULPHIDE BRIDGED DERIVATIVES AS MODULATORS OF MGLUR5 733 | GRM5, GRM3, GRIK5 | CA12 3977/4885BRD4 716/4885BRPF1 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.